Skip to main content

Unit information: Coronary Artery Disease II in 2015/16

Please note: you are viewing unit and programme information for a past academic year. Please see the current academic year for up to date information.

Unit name Coronary Artery Disease II
Unit code SOCSM0004
Credit points 20
Level of study M/7
Teaching block(s) Teaching Block 1 (weeks 1 - 12)
Unit director Professor. George
Open unit status Not open




School/department Bristol Medical School
Faculty Faculty of Health Sciences

Description including Unit Aims

This unit will expand on Unit 3 and provide further information and detail with regards to coronary artery disease. The current surgical interventions used for coronary artery disease (CABG and stent implantation) will be described, as well as the pathobiology of the numerous clinical complications that frequently occur as a result of these procedures, including neointima formation, thrombosis, cardioplegia, kidney and neurological damage. This unit’s main aim is to highlight the need for improved interventional treatments for coronary artery disease and the consequent value that pre-clinical (animal and in-vitro) models have in assessing the effectiveness of new therapeutic approaches. Finally, emerging new approaches that have been evaluated at the pre-clinical level for the treatment of coronary artery disease, such as the use of stem cells, altered stent coatings, novel clinical pharmacology approaches, micro-RNAs and gene therapy will be discussed.

Intended Learning Outcomes

Students successfully completing this module will be able to:

  • Discuss the currently used clinical treatments (surgical interventions) for coronary artery disease.
  • Outline the clinical problem of complications after treatment of coronary artery disease with CABG, PTCA or stents
  • Understand the pathobiology of the complications that occur after surgical interventional treatment for coronary artery disease.
  • Recognize the various pre-clinical models that are utilized for the assessment of new and emerging therapeutic approaches for the treatment of coronary artery disease.

Teaching Information

  • Web-based lectures, tutorials and practical demonstrations (in powerpoint-with-audio format)
  • Online discussion forum(s)
  • Self-directed study
  • Hands-on practical workshops held in Bristol.

Assessment Information

1. Coursework (contributing a total of 60% to the unit) consisting of:

  • 5 sets of multiple choice questions (MCQs) of a simple format (e.g. select an answer from a short number of options, true/false), each contributing 5% to the unit, giving a total of 25%.
  • 1 short essay contributing 20% to the unit.
  • 3 short answer question sets or extended MCQs, each contributing 5% to the unit, giving a total of 15%.

Please note that students will be given formative feedback on all coursework assessment.

2. Written exam (contributing a total of 40% to the unit and taken in Bristol) consisting of:

  • 1 essay contributing 20% to the unit.
  • 1 sets of MCQs contributing 20% to the unit.

The overall pass-mark for the unit will be 50%. However, students will be required to reach a minimum standard in both their coursework and their written exam; only 5% compensation between the total coursework element and the total exam element will be allowed.

Reading and References

  1. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW. Coronary revascularization trends in the United States, 2001-2008. JAMA. 2011;305(17):1769-76.
  2. Suzuki Y, Yeung AC, Ikeno F. The pre-clinical animal model in the translational research of interventional cardiology. JACC Cardiovasc Interv. 2009;2(5):373-83.
  3. Madonna R, De Caterina R.Stem cells and growth factor delivery systems for cardiovascular disease. J Biotechnol. 2011;154(4):291-7.
  4. Mariani JA, Kaye DM. Delivery of gene and cellular therapies for heart disease. J Cardiovasc Transl Res. 2010;3(4):417-26.
  5. Synetos A, Toutouzas K, Karanasos A, Stathogiannis K, Triantafyllou G, Tsiamis E, Lerakis S, Stefanadis C. Differences in drug-eluting stents used in coronary artery disease. Am J Med Sci. 2011 Nov;342(5):402-8.